|
|
|
| Effect of Somatostatin combined with Lansoprazole on Serum Gastrin, Inflammatory Factors and Adverse Reactions in Patients with Peptic Ulcer |
| LI Jing, WANG Dongxu, ZHU Hongbin, et al |
| 983 Hospital of PLA Joint Logistics Support Force, Tianjin 300142, China |
|
|
|
|
Abstract Objective: To investigate the effect of somatostatin combined with lansoprazole on serum gastrin, inflammatory factors and adverse reactions in patients with peptic ulcer (PU). Methods: 126 patients with PU in the hospital were selected as the subjects by simple random sampling method, and they were randomly divided into the control group and the observation group, 63 cases in each group. All patients were given basic treatments after admission. On the basis, the control group was treated with lansoprazole while the observation group was treated with somatostatin combined with lansoprazole. After 48h of medication, serum gastrin, motilin, somatostatin and other gastrointestinal hormones were compared between the two groups before and after treatment. The inflammatory factor, epidermal growth factor (EGF) and transforming growth factor alpha (TGF-ɑ) were detected, and adverse reactions in the two groups were statistically analyzed. Results: After treatment, levels of gastrin, motilin and somatostatin in the two groups were significantly lower than those before treatment, and the levels in the control group [(86.5±12.7) μmol/L, (208.4±31.2) pg/mL, (35.2±5.2) pg/mL] were significantly higher than those in the observation group [(71.3±10.6) μmol/L, (152.6±23.4) pg/mL, (27.9±4.1) pg/mL] (P<0.05). After treatment, inflammatory factors CRP and IL-6 in the two groups were decreased significantly, without significant difference between groups (P>0.05). Levels of EGF and TGF-ɑ in the two groups were significantly higher than those before treatment, and the levels in control group [(0.62±0.13) pg/mL, (2.45±0.47) pg/mL] were significantly lower than those in the observation group [(0.84±0.15) pg/mL, (2.63±0.51) pg/mL] (P<0.05). The total response rate of the control group was significantly lower than that of the observation group (66.7% vs 82.5%) (P<0.05), but there was no significant difference in the total incidence of adverse reactions between the two groups (15.9% vs 7.9%) (P>0.05). Conclusion: Somatostatin combined with lansoprazole can effectively relieve clinical symptoms of PU and promote the recovery of gastrointestinal function, without increasing adverse reactions and with high safety.
|
|
|
|
|
|
[1] 田晓娜.香砂六君子汤联合西药治疗消化性溃疡疗效分析[J].四川中医,2015,33(9):87~89.
[2] 罗金键.泮托拉唑治疗消化性溃疡合并上消化道出血的临床观察[J].中国医院用药评价与分析,2015,15(3):301~304.
[3] 王嫄嫄,陈洪波.2012年至2014年邢台地区上消化道出血临床特征分析[J].医学临床研究,2016,33(4):793~796.
[4] 张雪莲,王一平,吴维宇,等.四联疗法联合口腔洁治根除消化性溃疡合并幽门螺杆菌感染的疗效研究[J].成都医学院学报,2017,12(5):576~578.
[5] 赵红珍,王盖昊,王兆林,等.幽门螺杆菌感染与胃肠道疾病的研究进展[J].解放军医药杂志,2016,28(1):110~114.
[6] 张咏华,张锋,张欣,等.三联疗法治疗消化性溃疡的临床分析及预后分析[J].湖南师范大学学报(医学版),2015,12(5):83~85.
[7] Arici C,Mesci A,Dincer D,et al.Analysis of risk factors predicting(affecting)mortality and morbidity of peptic ulcer perforations[J].International Surgery,2016,92(3):147~154. |
|
|
|
2019, Vol. 25 
